PrognomiQ is a California-based biotechnology company that develops transformative test products for the early detection and treatment of cancer.
$34M
Nov 04, 2024
-
NovAliX is a France-based CRO that provides services such as drug discovery, process optimization, protein production and preclinical testing for the pharmaceutical industry.
-
Aug 06, 2024
-
Tome is a Massachusetts-based genome editing company that researches and develops gene-edited cell therapies for the treatment of autoimmune diseases.
$213M
Dec 11, 2023
-
Tome is a Massachusetts-based genome editing company that researches and develops gene-edited cell therapies for the treatment of autoimmune diseases.
-
Jul 11, 2023
-
Frequently Asked Questions about Bruker
What is Bruker investing in?
Bruker has invested in 17 companies including Terrain Biosciences, PrognomiQ and NovAliX
What company did Bruker invest in?
Bruker invested in a total 17 companies including Terrain Biosciences, PrognomiQ and NovAliX
What are the top 5 investments by Bruker?
The top companies in which Bruker invested are Terrain Biosciences, PrognomiQ, NovAliX, Tome Biosciences and Tome Biosciences
